Identifying cellular cancer mechanisms through pathway-driven data integration

Sam F L Windels1,2, Noël Malod-Dognin1,2, Nataša Pržulj1,2,3

  • 1Department of Computer Science, University College London, London WC1E 6BT, UK.

Abstract

Insights

We identified cancer pathways by analyzing changes in pathway relationships, not just gene expression. This approach predicts novel cancer-associated genes and potential drug targets.

Area of Science:

  • Computational biology
  • Systems biology
  • Genomics

Background:

  • Cancer is a genetic disease driven by mutations affecting cellular pathways.
  • Current methods focus on internal pathway perturbations, overlooking the role of driver genes as hubs between pathways.

Purpose of the Study:

  • To develop a novel method for identifying cancer pathways by analyzing changes in pathway-pathway relationships.
  • To predict cancer-associated genes and potential therapeutic targets.

Main Methods:

  • Pathway-driven non-negative matrix tri-factorization (NMTF) to learn pathway and gene embeddings.
  • Defining 'NMTF centrality' and 'moving distance' to assess functional importance and relationship changes.
  • Utilizing graphlet adjacency to model network data and identify hub driver genes.

Main Results:

  • Predicted 15 genes and pathways involved in four major cancers, yielding 60 gene-cancer associations.
  • Identified genes that rewire immune system pathway interactions.
  • Found 15 out of 28 predicted genes are druggable and 47 out of 60 associations are cancer-implicated.
  • Predicted six druggable, cancer-specific drug targets.

Conclusions:

  • Changes in pathway-pathway relationships are crucial for identifying cancer pathways.
  • The proposed method effectively predicts cancer-associated genes, their functional roles, and potential therapeutic targets.
  • This approach offers a new perspective for cancer pathway identification and drug discovery.

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.9K